Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion type Assertion NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_head.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion evidence source_evidence_literature NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion SIO_000772 16341239 NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion wasDerivedFrom befree-2016 NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.
- NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_assertion wasGeneratedBy ECO_0000203 NP526347.RA7asMOiAOhU6_ElBacf6t5VEzKq47kBJ5uUGwNX7PRRg130_provenance.